RII and RIII type resistance of Plasmodium falciparum to combination of mefloquine and sulfadoxine/pyrimethamine in Indonesia
2 of 36 Plasmodium falciparum infections were resistant (RII and RIII) in vivo to the combination of mefloquine (M) and sulfadoxine-pyrimethamine (SP) in Jayapura, Irian Jaya, Indonesia. Expected absorption of mefloquine and pyrimethamine was confirmed in the one resistant patient from whom sera wer...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1985-11, Vol.2 (8463), p.1039-1040 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1040 |
|---|---|
| container_issue | 8463 |
| container_start_page | 1039 |
| container_title | The Lancet (British edition) |
| container_volume | 2 |
| creator | Hoffman, S L Rustama, D Dimpudus, A J Punjabi, N H Campbell, J R Oetomo, H S Marwoto, H A Harun, S Sukri, N Heizmann, P |
| description | 2 of 36 Plasmodium falciparum infections were resistant (RII and RIII) in vivo to the combination of mefloquine (M) and sulfadoxine-pyrimethamine (SP) in Jayapura, Irian Jaya, Indonesia. Expected absorption of mefloquine and pyrimethamine was confirmed in the one resistant patient from whom sera were available, and the isolate from this patient was sensitive to mefloquine in vitro. Only 2 of 41 infections studied at the same time were resistant in vivo to SP. There was no clinical advantage of MSP compared with SP, and limited observations suggest there may be a disadvantage. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76449169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76449169</sourcerecordid><originalsourceid>FETCH-LOGICAL-p538-7065f23a85f8d3d6b4fba897e0c96dfd173b3219c8b9b151a8c7e28c802cc6573</originalsourceid><addsrcrecordid>eNotkEtLxDAUhbNQxnH0JwhZuSsmTfPoUgYfhQFFZl_yxEiT1KYFZ-F_NzPO6tzL-Tj3cC_AGuEGVYwTdgWuc_5CCDUM0RVY1YJRisUa_H50HZTRwKIdnA-jhZPNPs8yaguTg--DzCEZvwTo5KD9KKcyzgnqFJSPcvYpHrlg3ZC-Fx_tKS4vg5Mm_ZT9YTxMPtj5U4aj6yPsokmxXJE34LKEZnt71g3YPz_tt6_V7u2l2z7uqpESUXHEqKuJFNQJQwxTjVNStNwi3TLjDOZEkRq3WqhWYYql0NzWQgtUa80oJxtw_x87TqWizXMffNZ2GGS0ack9Z03TYtYW8O4MLipY04-luJwO_fld5A8cbGeb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76449169</pqid></control><display><type>article</type><title>RII and RIII type resistance of Plasmodium falciparum to combination of mefloquine and sulfadoxine/pyrimethamine in Indonesia</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hoffman, S L ; Rustama, D ; Dimpudus, A J ; Punjabi, N H ; Campbell, J R ; Oetomo, H S ; Marwoto, H A ; Harun, S ; Sukri, N ; Heizmann, P</creator><creatorcontrib>Hoffman, S L ; Rustama, D ; Dimpudus, A J ; Punjabi, N H ; Campbell, J R ; Oetomo, H S ; Marwoto, H A ; Harun, S ; Sukri, N ; Heizmann, P</creatorcontrib><description>2 of 36 Plasmodium falciparum infections were resistant (RII and RIII) in vivo to the combination of mefloquine (M) and sulfadoxine-pyrimethamine (SP) in Jayapura, Irian Jaya, Indonesia. Expected absorption of mefloquine and pyrimethamine was confirmed in the one resistant patient from whom sera were available, and the isolate from this patient was sensitive to mefloquine in vitro. Only 2 of 41 infections studied at the same time were resistant in vivo to SP. There was no clinical advantage of MSP compared with SP, and limited observations suggest there may be a disadvantage.</description><identifier>ISSN: 0140-6736</identifier><identifier>PMID: 2865518</identifier><language>eng</language><publisher>England</publisher><subject>Adolescent ; Adult ; Antimalarials - administration & dosage ; Antimalarials - pharmacology ; Antimalarials - therapeutic use ; Child ; Clinical Trials as Topic ; Drug Combinations - administration & dosage ; Drug Combinations - pharmacology ; Drug Resistance, Microbial ; Drug Therapy, Combination ; Female ; Humans ; Indonesia ; Malaria - drug therapy ; Malaria - parasitology ; Male ; Mefloquine ; Plasmodium falciparum - drug effects ; Pyrimethamine - administration & dosage ; Pyrimethamine - pharmacology ; Quinolines - pharmacology ; Quinolines - therapeutic use ; Random Allocation ; Sulfadoxine - administration & dosage ; Sulfadoxine - pharmacology ; Sulfanilamides - therapeutic use</subject><ispartof>The Lancet (British edition), 1985-11, Vol.2 (8463), p.1039-1040</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2865518$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoffman, S L</creatorcontrib><creatorcontrib>Rustama, D</creatorcontrib><creatorcontrib>Dimpudus, A J</creatorcontrib><creatorcontrib>Punjabi, N H</creatorcontrib><creatorcontrib>Campbell, J R</creatorcontrib><creatorcontrib>Oetomo, H S</creatorcontrib><creatorcontrib>Marwoto, H A</creatorcontrib><creatorcontrib>Harun, S</creatorcontrib><creatorcontrib>Sukri, N</creatorcontrib><creatorcontrib>Heizmann, P</creatorcontrib><title>RII and RIII type resistance of Plasmodium falciparum to combination of mefloquine and sulfadoxine/pyrimethamine in Indonesia</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>2 of 36 Plasmodium falciparum infections were resistant (RII and RIII) in vivo to the combination of mefloquine (M) and sulfadoxine-pyrimethamine (SP) in Jayapura, Irian Jaya, Indonesia. Expected absorption of mefloquine and pyrimethamine was confirmed in the one resistant patient from whom sera were available, and the isolate from this patient was sensitive to mefloquine in vitro. Only 2 of 41 infections studied at the same time were resistant in vivo to SP. There was no clinical advantage of MSP compared with SP, and limited observations suggest there may be a disadvantage.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antimalarials - administration & dosage</subject><subject>Antimalarials - pharmacology</subject><subject>Antimalarials - therapeutic use</subject><subject>Child</subject><subject>Clinical Trials as Topic</subject><subject>Drug Combinations - administration & dosage</subject><subject>Drug Combinations - pharmacology</subject><subject>Drug Resistance, Microbial</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Indonesia</subject><subject>Malaria - drug therapy</subject><subject>Malaria - parasitology</subject><subject>Male</subject><subject>Mefloquine</subject><subject>Plasmodium falciparum - drug effects</subject><subject>Pyrimethamine - administration & dosage</subject><subject>Pyrimethamine - pharmacology</subject><subject>Quinolines - pharmacology</subject><subject>Quinolines - therapeutic use</subject><subject>Random Allocation</subject><subject>Sulfadoxine - administration & dosage</subject><subject>Sulfadoxine - pharmacology</subject><subject>Sulfanilamides - therapeutic use</subject><issn>0140-6736</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotkEtLxDAUhbNQxnH0JwhZuSsmTfPoUgYfhQFFZl_yxEiT1KYFZ-F_NzPO6tzL-Tj3cC_AGuEGVYwTdgWuc_5CCDUM0RVY1YJRisUa_H50HZTRwKIdnA-jhZPNPs8yaguTg--DzCEZvwTo5KD9KKcyzgnqFJSPcvYpHrlg3ZC-Fx_tKS4vg5Mm_ZT9YTxMPtj5U4aj6yPsokmxXJE34LKEZnt71g3YPz_tt6_V7u2l2z7uqpESUXHEqKuJFNQJQwxTjVNStNwi3TLjDOZEkRq3WqhWYYql0NzWQgtUa80oJxtw_x87TqWizXMffNZ2GGS0ack9Z03TYtYW8O4MLipY04-luJwO_fld5A8cbGeb</recordid><startdate>19851109</startdate><enddate>19851109</enddate><creator>Hoffman, S L</creator><creator>Rustama, D</creator><creator>Dimpudus, A J</creator><creator>Punjabi, N H</creator><creator>Campbell, J R</creator><creator>Oetomo, H S</creator><creator>Marwoto, H A</creator><creator>Harun, S</creator><creator>Sukri, N</creator><creator>Heizmann, P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19851109</creationdate><title>RII and RIII type resistance of Plasmodium falciparum to combination of mefloquine and sulfadoxine/pyrimethamine in Indonesia</title><author>Hoffman, S L ; Rustama, D ; Dimpudus, A J ; Punjabi, N H ; Campbell, J R ; Oetomo, H S ; Marwoto, H A ; Harun, S ; Sukri, N ; Heizmann, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p538-7065f23a85f8d3d6b4fba897e0c96dfd173b3219c8b9b151a8c7e28c802cc6573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antimalarials - administration & dosage</topic><topic>Antimalarials - pharmacology</topic><topic>Antimalarials - therapeutic use</topic><topic>Child</topic><topic>Clinical Trials as Topic</topic><topic>Drug Combinations - administration & dosage</topic><topic>Drug Combinations - pharmacology</topic><topic>Drug Resistance, Microbial</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Indonesia</topic><topic>Malaria - drug therapy</topic><topic>Malaria - parasitology</topic><topic>Male</topic><topic>Mefloquine</topic><topic>Plasmodium falciparum - drug effects</topic><topic>Pyrimethamine - administration & dosage</topic><topic>Pyrimethamine - pharmacology</topic><topic>Quinolines - pharmacology</topic><topic>Quinolines - therapeutic use</topic><topic>Random Allocation</topic><topic>Sulfadoxine - administration & dosage</topic><topic>Sulfadoxine - pharmacology</topic><topic>Sulfanilamides - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoffman, S L</creatorcontrib><creatorcontrib>Rustama, D</creatorcontrib><creatorcontrib>Dimpudus, A J</creatorcontrib><creatorcontrib>Punjabi, N H</creatorcontrib><creatorcontrib>Campbell, J R</creatorcontrib><creatorcontrib>Oetomo, H S</creatorcontrib><creatorcontrib>Marwoto, H A</creatorcontrib><creatorcontrib>Harun, S</creatorcontrib><creatorcontrib>Sukri, N</creatorcontrib><creatorcontrib>Heizmann, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoffman, S L</au><au>Rustama, D</au><au>Dimpudus, A J</au><au>Punjabi, N H</au><au>Campbell, J R</au><au>Oetomo, H S</au><au>Marwoto, H A</au><au>Harun, S</au><au>Sukri, N</au><au>Heizmann, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RII and RIII type resistance of Plasmodium falciparum to combination of mefloquine and sulfadoxine/pyrimethamine in Indonesia</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>1985-11-09</date><risdate>1985</risdate><volume>2</volume><issue>8463</issue><spage>1039</spage><epage>1040</epage><pages>1039-1040</pages><issn>0140-6736</issn><abstract>2 of 36 Plasmodium falciparum infections were resistant (RII and RIII) in vivo to the combination of mefloquine (M) and sulfadoxine-pyrimethamine (SP) in Jayapura, Irian Jaya, Indonesia. Expected absorption of mefloquine and pyrimethamine was confirmed in the one resistant patient from whom sera were available, and the isolate from this patient was sensitive to mefloquine in vitro. Only 2 of 41 infections studied at the same time were resistant in vivo to SP. There was no clinical advantage of MSP compared with SP, and limited observations suggest there may be a disadvantage.</abstract><cop>England</cop><pmid>2865518</pmid><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1985-11, Vol.2 (8463), p.1039-1040 |
| issn | 0140-6736 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76449169 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adolescent Adult Antimalarials - administration & dosage Antimalarials - pharmacology Antimalarials - therapeutic use Child Clinical Trials as Topic Drug Combinations - administration & dosage Drug Combinations - pharmacology Drug Resistance, Microbial Drug Therapy, Combination Female Humans Indonesia Malaria - drug therapy Malaria - parasitology Male Mefloquine Plasmodium falciparum - drug effects Pyrimethamine - administration & dosage Pyrimethamine - pharmacology Quinolines - pharmacology Quinolines - therapeutic use Random Allocation Sulfadoxine - administration & dosage Sulfadoxine - pharmacology Sulfanilamides - therapeutic use |
| title | RII and RIII type resistance of Plasmodium falciparum to combination of mefloquine and sulfadoxine/pyrimethamine in Indonesia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T09%3A05%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RII%20and%20RIII%20type%20resistance%20of%20Plasmodium%20falciparum%20to%20combination%20of%20mefloquine%20and%20sulfadoxine/pyrimethamine%20in%20Indonesia&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Hoffman,%20S%20L&rft.date=1985-11-09&rft.volume=2&rft.issue=8463&rft.spage=1039&rft.epage=1040&rft.pages=1039-1040&rft.issn=0140-6736&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E76449169%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76449169&rft_id=info:pmid/2865518&rfr_iscdi=true |